Fig. 1
From: Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance
Elevated expression of MUC5AC in colorectal cancer patients and cell lines. a Expression of MUC5AC in colorectal cancer (CRC) patients (N = 287) and normal (N = 41) cases was analyzed in The Cancer Genome Atlas Program (TCGA) colorectal adenocarcinoma (COAD) dataset. A statistically significant difference was observed between normal vs cancer (***p < 0.001). b Immunohistochemistry staining of MUC5AC in a commercially available CRC tissue microarray (US Biomax, Rockville, United States). MUC5AC-positive staining is represented as a composite score. Representative images of differential MUC5AC staining in normal (N = 10), adenocarcinoma (N = 34, **p < 0.01), and metastatic adenocarcinoma (N = 20, **p < 0.01). c High expression of MUC5AC is associated with a decrease in overall and disease-free survival in CRC patients. d and e Quantitative real-time PCR and immunoblotting images showing decreased levels of MUC5AC expression in HCT-8 and LS174T cells. f Confocal images showing reduction in the MUC5AC expression in Sh5AC cell lines of both HCT-8 and LS174T by using MUC5AC primary antibody and stained with Alex Fluor secondary antibody (Red). Nuclear staining was carried out with DAPI (blue)